PUMA BIOTECHNOLOGY, INC. Amortization of Debt Issuance Costs
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Amortization of Debt Issuance Costs of $1.30 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2024-02-29
- PUMA BIOTECHNOLOGY, INC. amortization of debt issuance costs for the quarter ending 2023-12-31 was $700.00K, a 16.67% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. amortization of debt issuance costs for the quarter ending 2023-09-30 was $200.00K, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. amortization of debt issuance costs for the quarter ending 2023-06-30 was $200.00K, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. amortization of debt issuance costs for the quarter ending 2023-03-31 was $200.00K, a 0.00% change year-over-year.
- PUMA BIOTECHNOLOGY, INC. amortization of debt issuance costs for fiscal 2023 was $1.30M, a 8.33% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. amortization of debt issuance costs for fiscal 2022 was $1.20M, a 53.85% decline from fiscal 2021.
- PUMA BIOTECHNOLOGY, INC. amortization of debt issuance costs for fiscal 2021 was $2.60M, a 30.00% increase from fiscal 2020.
- PUMA BIOTECHNOLOGY, INC. amortization of debt issuance costs for fiscal 2020 was $2.00M, a 33.33% increase from fiscal 2019.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $700.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $900.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.10M derived: sum of 3 quarters · filed 2024-02-29 | $1.30M 10-K · filed 2024-02-29 |
| 2023-09-30 | $200.00K 10-Q · filed 2023-11-02 | $400.00K derived: sum of 2 quarters · filed 2023-11-02 | $600.00K 10-Q · filed 2023-11-02 | $1.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | $200.00K 10-Q · filed 2023-08-03 | $400.00K 10-Q · filed 2023-08-03 | $1.00M derived: sum of 3 quarters · filed 2024-02-29 | $1.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | $200.00K derived: 10-K 12 month − 3 quarters · filed 2024-02-29 | $800.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.00M derived: sum of 3 quarters · filed 2024-02-29 | $1.20M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $800.00K derived: sum of 2 quarters · filed 2024-02-29 | $1.00M derived: sum of 3 quarters · filed 2024-02-29 | $1.20M 10-K · filed 2024-02-29 |
| 2022-09-30 | $200.00K 10-Q · filed 2023-11-02 | $400.00K derived: sum of 2 quarters · filed 2023-11-02 | $600.00K 10-Q · filed 2023-11-02 | $1.70M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-03 | $400.00K 10-Q · filed 2023-08-03 | $1.50M derived: sum of 3 quarters · filed 2024-02-29 | $1.90M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $200.00K 10-Q · filed 2023-05-04 | $1.30M derived: sum of 2 quarters · filed 2024-02-29 | $1.70M derived: sum of 3 quarters · filed 2024-02-29 | $2.30M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.50M derived: sum of 2 quarters · filed 2024-02-29 | $2.10M derived: sum of 3 quarters · filed 2024-02-29 | $2.60M 10-K · filed 2024-02-29 |
| 2021-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.50M 10-Q · filed 2022-11-03 | $2.10M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.10M 10-Q · filed 2022-08-04 | $1.70M derived: sum of 3 quarters · filed 2023-03-02 | $2.20M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $500.00K 10-Q · filed 2022-05-05 | $1.10M derived: sum of 2 quarters · filed 2023-03-02 | $1.60M derived: sum of 3 quarters · filed 2023-03-02 | $2.00M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $1.10M derived: sum of 2 quarters · filed 2023-03-02 | $1.50M derived: sum of 3 quarters · filed 2023-03-02 | $2.00M 10-K · filed 2023-03-02 |
| 2020-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $900.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.40M 10-Q · filed 2021-11-04 | $1.80M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $900.00K 10-Q · filed 2021-08-05 | $1.30M derived: sum of 3 quarters · filed 2022-03-03 | |
| 2020-03-31 | $500.00K 10-Q · filed 2021-05-06 | $900.00K derived: sum of 2 quarters · filed 2022-03-03 | ||
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $1.50M 10-K · filed 2022-03-03 | ||
| 2019-09-30 | $1.10M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $900.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |